Skip to content

Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions

Validation of Clinical Biomarkers Using Spatial Transcriptomics and Development of a Diagnostic Test to Characterize the Progression Potential of Cutaneous Precancerous Lesions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07624981
Acronym
DIAGNO-KA
Enrollment
140
Registered
2026-06-03
Start date
2026-02-01
Completion date
2026-06-30
Last updated
2026-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diagnostic, Skin Cancer

Brief summary

Actinic keratoses are precancerous skin lesions that are the most common among all cancers and precancerous conditions in fair-skinned populations. The distinctive feature of these actinic keratoses is that some progress into skin cancers known as cutaneous carcinomas, while others regress spontaneously; currently, there is no way to distinguish between them, either through clinical observation or biological methods. The goal of the Diagno-KA project is to develop a diagnostic test that would distinguish between actinic keratoses that progress to cancer-so they can be surgically removed early (before they become severe and metastasize)-and those that regress, thereby avoiding unnecessary surgical intervention (to prevent scarring).

Interventions

None listed

Sponsors

Centre Hospitalier Régional Metz-Thionville
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with skin carcinomas and actinic keratoses

Exclusion criteria

* minor patient

Design outcomes

Primary

MeasureTime frame
Biomarker validationUntil the end of the study on average 2 years

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 4, 2026